Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition
Related Experiment Video
Updated: Jun 8, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Liping Zhang1, Chee M Ng, James F List
1Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey, USA. liping.zhang3@bms.com
Abstract:
Advances in experimental medicine and technological innovation during the past century have brought tremendous progress in modern medicine and generated an ever-increasing amount of data from bench and bedside. The desire to extend scientific knowledge motivates effective data integration. Technological innovation makes this possible, which in turn accelerates the advancement in science. This mutually beneficial interaction is illustrated by the development of an expanded mechanism-based model for understanding a novel mechanism, sodium-glucose cotransporter-2 SGLT2 inhibition for potential treatment of type 2 diabetes mellitus.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Secondary Active Transport
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucose Absorption Into the Small Intestine
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...